SG11202003098WA - Oral bendamustine formulations - Google Patents

Oral bendamustine formulations

Info

Publication number
SG11202003098WA
SG11202003098WA SG11202003098WA SG11202003098WA SG11202003098WA SG 11202003098W A SG11202003098W A SG 11202003098WA SG 11202003098W A SG11202003098W A SG 11202003098WA SG 11202003098W A SG11202003098W A SG 11202003098WA SG 11202003098W A SG11202003098W A SG 11202003098WA
Authority
SG
Singapore
Prior art keywords
bendamustine formulations
oral bendamustine
oral
formulations
bendamustine
Prior art date
Application number
SG11202003098WA
Inventor
Wolfgang Richter
Original Assignee
Tube Pharmaceuticals Gmbh
Mecox Curemed Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tube Pharmaceuticals Gmbh, Mecox Curemed Co Ltd filed Critical Tube Pharmaceuticals Gmbh
Publication of SG11202003098WA publication Critical patent/SG11202003098WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
SG11202003098WA 2017-10-05 2018-10-05 Oral bendamustine formulations SG11202003098WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17194987 2017-10-05
PCT/EP2018/077214 WO2019068904A1 (en) 2017-10-05 2018-10-05 Oral bendamustine formulations

Publications (1)

Publication Number Publication Date
SG11202003098WA true SG11202003098WA (en) 2020-05-28

Family

ID=60022004

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003098WA SG11202003098WA (en) 2017-10-05 2018-10-05 Oral bendamustine formulations

Country Status (14)

Country Link
US (1) US20200246312A1 (en)
EP (1) EP3691637A1 (en)
JP (1) JP7267290B2 (en)
KR (2) KR102450975B1 (en)
CN (1) CN111201019A (en)
AU (1) AU2018346395A1 (en)
BR (1) BR112020006360A2 (en)
CA (1) CA3078290A1 (en)
IL (1) IL273644A (en)
MX (1) MX2020003511A (en)
RU (1) RU2020115024A (en)
SG (1) SG11202003098WA (en)
WO (1) WO2019068904A1 (en)
ZA (1) ZA202002129B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11583536B2 (en) * 2019-10-21 2023-02-21 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use
CN115379827A (en) * 2020-04-09 2022-11-22 比卡生物科技（广州）有限公司 Bendamustine compositions and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR072777A1 (en) 2008-03-26 2010-09-22 Cephalon Inc SOLID FORMS OF BENDAMUSTINE CHLORHYDRATE
CA2735899A1 (en) 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
DK2367542T3 (en) 2008-12-03 2014-03-10 Astellas Deutschland Gmbh ORAL DOSAGE FORMS OF BENDAMUSTIN
UA107186C2 (en) 2008-12-03 2014-12-10 SOLID FORMS OF BENDAMUSTINE DOSAGE
RU2734236C2 (en) * 2009-02-25 2020-10-13 Софткемо Фарма Корп. Bendamustine and cyclopolysaccharide compositions
MX2011011109A (en) 2009-04-28 2011-11-18 Cephalon Inc Oral formulations of bendamustine.
WO2010144675A1 (en) 2009-06-10 2010-12-16 Plus Chemicals Sa Polymorphs of bendamustine hcl and processes for preparation thereof
CN101606934B (en) 2009-07-27 2011-09-28 江苏奥赛康药业有限公司 Bendamustine hydrochloride compound
WO2011103150A2 (en) 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
US8383663B2 (en) * 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
CN102351799B (en) 2011-10-24 2014-02-26 江苏奥赛康药业股份有限公司 Bendamustine hydrochloride crystal and preparation method thereof
PT2656843E (en) 2012-04-26 2015-04-14 Helmut Schickaneder Esters of bendamustine and related compounds, and medical use thereof

Also Published As

Publication number Publication date
MX2020003511A (en) 2020-07-22
WO2019068904A1 (en) 2019-04-11
RU2020115024A3 (en) 2022-03-17
KR20200066657A (en) 2020-06-10
KR20220138420A (en) 2022-10-12
ZA202002129B (en) 2023-10-25
KR102450975B1 (en) 2022-10-07
BR112020006360A2 (en) 2020-09-24
EP3691637A1 (en) 2020-08-12
IL273644A (en) 2020-05-31
AU2018346395A1 (en) 2020-04-30
JP7267290B2 (en) 2023-05-01
CA3078290A1 (en) 2019-04-11
JP2020536126A (en) 2020-12-10
RU2020115024A (en) 2021-11-08
US20200246312A1 (en) 2020-08-06
CN111201019A (en) 2020-05-26

Similar Documents

Publication Publication Date Title
IL273541A (en) Formulations
IL268697A (en) Formulations
IL275213B (en) Oral care implement
GB2559774B (en) Oral cannabinoid formulations
ZAA201800037S (en) Oral care devices
ZA201903452B (en) Oral care compositions
IL257658B (en) Oral care compositions
GB201611547D0 (en) Oral cannabinoid formulations
IL269630A (en) Niraparib formulations
IL259211A (en) Oral care implement
IL269621A (en) Niraparib formulations
ZA201903460B (en) Oral care compositions
IL257659B (en) Oral care compositions
IL273282A (en) Niraparib formulations
IL259044B (en) Oral care compositions
ZA201807771B (en) Oral care compositions
AU201812863S (en) Oral Care Implement
ZA201903431B (en) Oral care compositions
ZA201807730B (en) An oral care composition
ZA201706785B (en) Oral care compositions
ZA201903379B (en) Oral care compositions
ZA201903451B (en) Oral care compositions
ZA201903430B (en) Oral care compositions
HK1259305A1 (en) Oral care implement
ZA201803909B (en) Oral care compositions